Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2022

Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2022

DelveInsight’s, “Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Bronchiolitis Obliterans Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Bronchiolitis Obliterans Syndrome Understanding

Bronchiolitis Obliterans Syndrome: Overview

Bronchiolitis obliterans syndrome (BOS) is a form of chronic lung allograft dysfunction that affects the majority of lung transplant recipients. It is the principal factor limiting long-term transplant survival. BOS is characterized by progressive airflow obstruction unexplained by acute rejection, infection, or other coexistent condition. Although BOS is a proven useful clinical syndrome that identifies patients at increased risk for death, its clinical course and underlying causative factors are now recognized to be increasingly heterogeneous. It is an uncommon respiratory disease characterized by fixed airway obstruction, where the bronchioles in the lung narrow down or get blocked by fibrous tissue. The disease is disabling and can be potentially severe. It may be caused occupationally by accidental, acute, high concentration exposure to industrial gases, such as nitrogen dioxide, etc. It manifests mainly by abnormal remodeling of the small airways (bronchioles), resulting in progressive airflow obstruction called Bronchiolitis Obliterans Syndrome (BOS).

""Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bronchiolitis Obliterans Syndrome pipeline landscape is provided which includes the disease overview and Bronchiolitis Obliterans Syndrome treatment guidelines. The assessment part of the report embraces, in depth Bronchiolitis Obliterans Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
 
Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence in Bronchiolitis Obliterans Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve in Bronchiolitis Obliterans Syndrome.

This segment of the Bronchiolitis Obliterans Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bronchiolitis Obliterans Syndrome Emerging Drugs

Liposomal Cyclosporine A: Zambon

Liposomal Cyclosporine A for Inhalation (LCsAi) is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. LCsAi is administered via a drug-specific Investigational eFlow Technology nebulizer system (PARI Pharma GmbH). The investigational drug-device combination is designed to deliver LCsAi to the site of disease in the lung. LCsAi has received orphan drug designation for the treatment of BOS from the US Food and Drug Administration and European Medicines Agency. Currently the drug, is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Bronchiolitis Obliterans.

Further product details are provided in the report……..

Bronchiolitis Obliterans Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Bronchiolitis Obliterans Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bronchiolitis Obliterans Syndrome

There are approx. 5+ key companies which are developing the therapies for Bronchiolitis Obliterans Syndrome. The companies which have their Bronchiolitis Obliterans Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zambon.

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Bronchiolitis Obliterans Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bronchiolitis Obliterans Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bronchiolitis Obliterans Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchiolitis Obliterans Syndrome drugs.

Bronchiolitis Obliterans Syndrome Report Insights

Bronchiolitis Obliterans Syndrome Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Bronchiolitis Obliterans Syndrome Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs
 
Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Bronchiolitis Obliterans Syndrome drugs?

How many Bronchiolitis Obliterans Syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchiolitis Obliterans Syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bronchiolitis Obliterans Syndrome?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Bronchiolitis Obliterans Syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Zambon

Genentech

Incyte Corporation

Mereo BioPharma

Incyte Corporation

Key Products

Liposomal Cyclosporine A

Pirfenidone

Ruxolitinib

Alvelestat

Itacitinib